The poster selected for the Hot Topics session on July 14, 11:30 AM – 1:00 PM is authored by Hans-Ulrich Demuth, CSO and co-founder of Probiodrug and two Alzheimer specialists from the US: George S.
In addition, the Hot Topic Poster presents for the first time, that the neurotoxicity of the pGlu-Abeta peptide driven oligomer formation is strictly Tau-protein dependent. While it was assumed for a long time following their discovery that the QC enzymes show a strict specificity for glutamine in the N-terminal position of peptides and proteins, Probiodrug discovered that all (plant, bacterial and mammalian) QCs can perform under certain conditions also the conversion of a N-terminal glutamate to form the so-called pyroglutamated (pGlu) peptide species. The enzyme in question is glutaminyl cyclase (QC), an enzyme catalyzing the formation of pyroglutamic peptides or proteins from an N-terminal glutamine residue. The findings that not all of the amyloid beta protein, which is in the focus of Alzheimer research for decades, but only a particular, pyroglutamated version of it, is toxic, highly abundant in the brain of Alzheimer patients and can – at least in animal models – be attenuated by either passive immunization or by inhibition of the enzyme producing this modification, has been selected for presentation in this year’s Hot Topics Poster Session. Halle/Saale, JProbiodrug AG (Probiodrug), a biotech company developing novel concepts and products for the treatment of neurodegenerative and inflammatory diseases with a particular focus on Alzheimer’s disease, today announced that the Company will present four posters featuring its latest research results about a unique pathway possibly involved in the onset and progression of Alzheimer’s disease at the upcoming International Conference on Alzheimer’s Disease (ICAD, July 10-15) in Hawaii (USA).
0 kommentar(er)
